Header Logo

Jieni Li

TitleAssociate Professor
InstitutionUniversity of Houston
DepartmentPharmaceutical Health Outcomes and Policy
Address4800 Calhoun Rd
Houston TX 77004
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chikermane SG, Li J, Aparasu RR. Risk of Antipsychotic Initiation Among Older Dementia Patients Initiating Cholinesterase Inhibitors. Drug Healthc Patient Saf. 2025; 17:75-85. PMID: 40129750; PMCID: PMC11932038.
      Citations:    
    2. Olateju OA, Li J, Thornton JD, Aparasu RR. Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374. PMID: 39612258; PMCID: PMC11607212.
      Citations:    Fields:    Translation:Humans
    3. Li J, Hutton GJ, Varisco TJ, Lin Y, Essien EJ, Aparasu RR. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180. PMID: 39557306.
      Citations:    Fields:    Translation:Humans
    4. Li J, Hutton GJ, Varisco TJ, Lin Y, Essien EJ, Aparasu RR. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569. PMID: 39547934.
      Citations:    Fields:    
    5. Li J, Hutton GJ, Varisco TJ, Lin Y, Essien EJ, Aparasu RR. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896. PMID: 39342811.
      Citations:    Fields:    Translation:Humans
    6. Chikermane SG, Li J, Aparasu RR. Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease. Arch Gerontol Geriatr. 2025 Jan; 128:105629. PMID: 39303423.
      Citations:    Fields:    Translation:Humans
    7. Huang Y, Li J, Agarwal SK. Economic and Humanistic Burden of Rheumatoid Arthritis: Results From the US National Survey Data 2018-2020. ACR Open Rheumatol. 2024 Nov; 6(11):746-754. PMID: 39105293; PMCID: PMC11557984.
      Citations:    
    8. Earla JR, Li J, Hutton GJ, Bentley JP, Aparasu RR. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539. PMID: 38574721.
      Citations:    Fields:    Translation:Humans
    9. Huang Y, Li J, Li M, Aparasu RR. Application of machine learning in predicting survival outcomes involving real-world data: a scoping review. BMC Med Res Methodol. 2023 11 13; 23(1):268. PMID: 37957593; PMCID: PMC10641971.
      Citations: 2     Fields:    
    10. Li J, Huang Y, Hutton GJ, Aparasu RR. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023 Sep; 11:100307. PMID: 37554927; PMCID: PMC10405092.
      Citations:    
    11. Earla JR, Li J, Hutton GJ, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484. PMID: 37157135.
      Citations:    Fields:    Translation:Humans
    12. Zakeri M, Li J, Sansgiry SS, Aparasu RR. Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data. J Manag Care Spec Pharm. 2023 May; 29(5):480-489. PMID: 37121258; PMCID: PMC10387904.
      Citations: 1     Fields:    Translation:Humans
    13. Atanda F, Li J, Cho SK. Improving utility of prescription drug monitoring programs with more accurate patient information. Fam Pract. 2022 Jul 19; 39(4):773-774. PMID: 34596689.
      Citations:    Fields:    Translation:Humans
    14. Li J, Zakeri M, Hutton GJ, Aparasu RR. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019. PMID: 35839614.
      Citations: 1     Fields:    Translation:Humans
    15. Li J, Chikermane SG, Earla JR, Hutton GJ, Aparasu RR. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703. PMID: 35278846.
      Citations: 1     Fields:    Translation:Humans
    Li's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (55)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Same Department Expand Description
    Explore
    _